Albert David Ltd AI Stock Analysis
Want to see IN:ALBERTDAVD full AI Analyst Report?
Albert David Ltd (ALBERTDAVD) AI Stock Analysis
Albert David Ltd
(NSE:ALBERTDAVD)
The score is driven primarily by a severe fundamental downturn: falling revenue, a swing from strong profits to an operating and net loss, halved gross profit, and two straight years of negative operating and free cash flow funded by rising debt. A still-solid equity base and historically low leverage prevent a lower score, but the trend is unfavourable. Technicals are neutral at best - the stock holds above its 200-day average yet trades below the 50-day with negative MACD and mid-range momentum readings. Valuation offers little protection, as the 15.5x P/E reflects earnings that have already evaporated and the 0.63% yield is thin. Without evidence of a margin and cash flow turnaround, this remains a high-risk situation.
Albert David Ltd (ALBERTDAVD) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 4.34B
- Dividend Yield
- 0.66%
- Average Volume (3M)
- 268
- Price to Earnings (P/E)
- 15.1
- Beta (1Y)
- 1.04
- Revenue Growth
- 19.69%
- EPS Growth
- ―
- Country
- India
- Employees
- 1,476
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Albert David Ltd Business Overview & Revenue Model
Company Description
Albert David Limited is an Indian pharmaceutical company specializing in the production and distribution of a diverse array of medical products. Its offerings encompass pharmaceutical formulations, intravenous solutions, herbal medicines, bulk drug s...
Albert David Ltd Financial Statement Overview
Summary
Fundamentals have deteriorated sharply. Revenue has declined for two consecutive years (₹3.60B in FY2024 to a projected ₹3.34B in FY2026), while net income collapsed from ₹754M to a loss of ₹15M and EBIT turned negative. Gross profit halved from ₹2.3B to ₹1.1B, pointing to structural cost or pricing pressure rather than a temporary setback. Cash flow is the weakest link, with operating cash flow negative for two years and free cash flow at -₹433M and -₹351M, forcing reliance on borrowings. The balance sheet is the only relative cushion: equity has grown to ₹3.92B and leverage remains low in absolute terms, but total debt more than doubled to ₹297M and ROE fell from ~20% to ~4.4%, so even this strength is eroding.
Income Statement
28NegativeBalance Sheet
52NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.64B | 3.34B | 3.46B | 3.60B | 3.42B | 3.12B |
| Gross Profit | 1.30B | 1.07B | 2.29B | 2.32B | 2.18B | 1.95B |
| EBITDA | -2.27M | 129.20M | 30.26M | 1.05B | 598.68M | 567.76M |
| Net Income | 225.66M | -14.95M | 172.01M | 754.20M | 361.75M | 352.58M |
Balance Sheet | ||||||
| Total Assets | 0 | 5.19B | 5.11B | 4.98B | 4.23B | 4.03B |
| Cash, Cash Equivalents and Short-Term Investments | 2.58B | 2.58B | 2.44B | 2.85B | 2.03B | 1.75B |
| Total Debt | 0 | 297.11M | 123.17M | 33.24M | 53.18M | 56.62M |
| Total Liabilities | -3.92B | 1.28B | 1.19B | 1.15B | 1.12B | 1.23B |
| Stockholders Equity | 3.92B | 3.92B | 3.92B | 3.83B | 3.12B | 2.79B |
Cash Flow | ||||||
| Free Cash Flow | -271.21M | -350.95M | -432.92M | 346.28M | 52.78M | 292.83M |
| Operating Cash Flow | -208.45M | -59.83M | -284.36M | 455.02M | 105.15M | 403.65M |
| Investing Cash Flow | -46.97M | -85.53M | 233.01M | -332.48M | -49.95M | -396.97M |
| Financing Cash Flow | 248.82M | 144.00M | 1.10M | -82.70M | -63.62M | -12.59M |
Albert David Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 753.60 is below the 20-day moving average (MA) of 775.77, below the 50-day MA of 813.62, and above the 200-day MA of 742.45, indicating a neutral trend. The MACD of -8.71 indicates Negative momentum. The RSI at 39.52 is Neutral, neither overbought nor oversold. The STOCH value of 11.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.
Albert David Ltd Peers Comparison
Overall Rating
IN:IOLCP72Outperform
IN:APLLTD71Outperform
IN:GLENMARK66Neutral
IN:IPCALAB58Neutral
IN:UNICHEMLAB51Neutral
IN:ALBERTDAVD40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | INR 55.74B | 27.42 | ― | 0.53% | 26.76% | 75.41% | |
| 71Outperform | INR 205.12B | 24.33 | ― | 1.15% | 19.68% | 33.03% | |
| 66Neutral | INR 749.31B | 51.45 | ― | 0.19% | -0.11% | 43.72% | |
| 58Neutral | INR 470.33B | 33.54 | ― | 0.32% | 11.99% | 68.61% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | INR 34.01B | 9.95 | ― | ― | 6.44% | 283.10% | |
| 40Underperform | INR 4.30B | 15.08 | ― | 0.66% | 19.69% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ALBERTDAVD | Albert David Ltd | 753.60 | -29.76 | -3.80% | |
| IN:APLLTD | Alembic Pharmaceuticals Limited | 1043.55 | 154.73 | 17.41% | |
| IN:GLENMARK | Glenmark Pharmaceuticals Limited | 2655.00 | 811.68 | 44.03% | |
| IN:IOLCP | IOL Chemicals & Pharmaceuticals Ltd. | 189.90 | 100.80 | 113.13% | |
| IN:IPCALAB | IPCA Laboratories Limited | 1854.20 | 415.35 | 28.87% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 483.05 | 15.25 | 3.26% |
Albert David Ltd Corporate Events
Albert David Board Approves Unaudited Results for September 2026 Period
Albert David Limited submitted its unaudited financial results for the quarter and half year ended September 30, 2026. The Board approved and took the results on record at its November 12, 2026 meeting, along with the Statutory Auditor’s Limited Revi...
Albert David files SEBI demat compliance certificate for Q2 FY27
Albert David Ltd has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate, issued by registrar and share transfer agent Mahes...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
